Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitors (cBTKis) or B-cell lymphoma 2 inhibitors (BCL2is) | Publicación